Nomura released a research report stating that the target price for minimally invasive medical treatment (00853.HK) was rated “neutral” and the target price was reduced by 7% from HK$7.19 to HK$6.71.
野村：予微创医疗(00853.HK)“中性”评级 目标价降至6.71港元
Nomura: Target price for Minimally Invasive Medicine (00853.HK) “neutral” rating reduced to HK$6.71
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.